Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Giulia MarvasoG CorraoO OnetaM PepaM ZaffaroniF CorsoS GandiniA CecconiD ZeriniG C MazzolaM AugugliaroM Cossu RoccaE VerriF CattaniF La FauciL BergamaschiS LuzzagoA F MistrettaG MusiF NolèO De CobelliR OrecchiaB A Jereczek-FossaPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2021)
The pattern of failure was pre-dominantly out-of-field, even if the population was negatively selected and the used RT dose could be considered palliative. Therefore, SBRT appears to be a well-tolerated, feasible and safe approach in oligo metastatic RCC patients with an excellent in-field PFS. SBRT might play a role in the management of selected RCC patients allowing for a delay systemic therapy begin (one out of two patients were free from new systemic therapy at 2 years after SBRT). Further research on SBRT dose escalation is warranted.